The IGF-trap: Novel inhibitor of carcinoma growth and metastasis

Molecular Cancer Therapeutics

Volumn 14, Issue 4, 2015, Pages 982-993

  Wang, Ni ^a   Rayes, Roni F ^a   Elahi, Seyyed Mehdy ^b   Lu, Yifan ^a   Hancock, Mark A ^c   Massie, Bernard ^b   Rowe, Gerald E ^b   Aomari, Hafida ^b   Hossain, Sazzad ^b   Durocher, Yves ^b   Pinard, Maxime ^a   Tabariès, Sébastien ^a,d   Siegel, Peter M ^a,d   Brodt, Pnina ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; CD31 ANTIGEN; INSULIN; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECEPTOR ANTIBODY; RECOMBINANT PROTEIN; SOLUBLE INSULIN LIKE GROWTH FACTOR 1 RECEPTOR IMMUNOGLOBULIN G1 FC FRAGMENT FUSION PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HYBRID PROTEIN; PROTEIN BINDING; SOMATOMEDIN B;

ANCHORAGE INDEPENDENT GROWTH; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BREAST CARCINOMA; CANCER INHIBITION; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHO CELL LINE; COLON CARCINOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; EXPERIMENTAL LIVER METASTASIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; MAXIMUM PLASMA CONCENTRATION; METASTASIS INHIBITION; MICROMETASTASIS; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SURFACE PLASMON RESONANCE; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; CARCINOMA; CHEMISTRY; CRICETULUS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; HUMAN; ISOLATION AND PURIFICATION; KINETICS; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CHO CELLS; CRICETULUS; DISEASE MODELS, ANIMAL; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; KINETICS; MICE; NEOPLASM METASTASIS; PROTEIN BINDING; RECEPTOR, IGF TYPE 1; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955465716     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0751     Document Type: Article

References (61)

1. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47.
2. Zhang D, Samani AA, Brodt P. The role of the IGF-I receptor in the regulation of matrix metalloproteinases, tumor invasion and metastasis. Horm Metab Res 2003;35:802-8.
3. Seccareccia E, Brodt P. The role of the insulin-like growth factor-I receptor in malignancy: an update. Growth Horm IGF Res 2012;22:193-9.
4. Sachdev D. Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer. Curr Opin Mol Ther 2007;9:299-304.
5. Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 2006;66:2391-402.
6. Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, et al. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res 2011;71:1029-40.
7. Friedbichler K, Hofmann MH, Kroez M, Ostermann E, Lamche HR, Koessl C, et al. Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin. Mol Cancer Ther 2014;13:399-409.
8. Alami N, Page V, Yu Q, Jerome L, Paterson J, Shiry L, et al. Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Horm IGF Res 2008;18:487-96.
9. Van den Berg CL, Cox GN, Stroh CA, Hilsenbeck SG, Weng CN,McDermott MJ, et al. Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer 1997;33:1108-13.
10. Arnaldez FI, Helman LJ. Targeting the insulin growth factor receptor 1. Hematol Oncol Clin North Am 2012;26:527-42, vii-viii.
11. Chen HX, Sharon E. IGF-1R as an anti-cancer target-trials and tribulations. Chinese J Cancer 2013;32:242-52.
12. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;12:159-69.
13. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009;28:3009-21.
14. Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, et al. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 2009;69:2443-52.
15. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, et al. Compensatory insulin receptor (IR) activation on inhibition of insulinlike growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther 2010;9:2652-64.
16. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulinlike growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999;19:3278-88.
17. Girnita L, Worrall C, Takahashi S, Seregard S, Girnita A. Something old, something new and something borrowed: emerging paradigm of insulinlike growth factor type 1 receptor (IGF-1R) signaling regulation. Cell Mol Life Sci 2014;71:2403-27.
18. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGFTrap: a VEGF blockerwith potent antitumor effects. Proc Natl Acad SciUSA 2002;99:11393-8.
19. Trieu Y, Wen XY, Skinnider BF, Bray MR, Li Z, Claudio JO, et al. Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo. Cancer Res 2004;64:3271-5.
20. Tseng JF, Farnebo FA, Kisker O, Becker CM, Kuo CJ, Folkman J, et al. Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice. Surgery 2002;132:857-65.
21. Messori A, Santarlasci B, Vaiani M. New drugs for rheumatoid arthritis. N Engl J Med 2004;351:937-8.
22. D'Ambrosio C, Ferber A, Resnicoff M, Baserga R. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res 1996;56:4013-20.
23. Samani AA, Chevet E, Fallavollita L, Galipeau J, Brodt P. Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor. Cancer Res 2004;64:3380-5.
24. Wang N, Fallavollita L, Nguyen L, Burnier J, Rafei M, Galipeau J, et al. Autologous bone marrowstromal cells genetically engineered to secrete an igf-I receptor decoy prevent the growth of liver metastases. Mol Ther 2009;17:1241-9.
25. Wang N, Lu Y, Pinard M, Pilotte A, Gilbert R, Massie B, et al. Sustained production of a soluble IGF-I receptor by gutless adenovirus-transduced host cells protects from tumor growth in the liver. Cancer Gene Ther 2013;20:229-36.
26. Didion JP, Buus RJ, Naghashfar Z, Threadgill DW,Morse HC3rd, de Villena FP. SNP array profiling of mouse cell lines identifies their strains of origin and reveals cross-contamination and widespread aneuploidy. BMC Genomics 2014;15:847.
27. Brodt P. Characterization of two highly metastatic variants of Lewis lung carcinoma with different organ specificities. Cancer Res 1986; 46:2442-8.
28. Tabaries S, Dong Z, Annis MG, Omeroglu A, Pepin F, Ouellet V, et al. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene 2011;30:1318-28.
29. Calzone FJ, Cajulis E, Chung YA, Tsai MM, Mitchell P, Lu J, et al. Epitopespecific mechanisms of IGF1R inhibition by ganitumab. PLoS ONE 2013;8:e55135.
30. Gilbert RBS,Massie B. Protein production using lentiviral vectors. In:Dyson MRDY, editor. Methods express: expression systems. Oxfordshire: Scion Publishing Ltd; 2007. p. 241-58.
31. Gaillet B, Gilbert R, Broussau S, Pilotte A, Malenfant F, Mullick A, et al. High-level recombinant protein production in CHO cells using lentiviral vectors and the cumate gene-switch. Biotechnol Bioeng 2010;106:203-15.
32. Myszka DG. Improving biosensor analysis. J Mol Recognit 1999;12: 279-84.
33. Beattie J, Phillips K, Shand JH, Szymanowska M, Flint DJ, Allan GJ. Molecular interactions in the insulin-like growth factor (IGF) axis: a surface plasmon resonance (SPR) based biosensor study. Mol Cell Biochem 2008;307:221-36.
34. Forbes BE, Hartfield PJ, McNeil KA, Surinya KH, Milner SJ, Cosgrove LJ, et al. Characteristics of binding of insulin-like growth factor (IGF)-I and IGF-II analogues to the type 1 IGF receptor determined by BIAcore analysis. Eur J Biochem 2002;269:961-8.
35. Jansson M, Dixelius J, Uhlen M, Nilsson BO. Binding affinities of insulinlike growth factor-I (IGF-I) fusion proteins to IGF binding protein 1 and IGF-I receptor are not correlated with mitogenic activity. FEBS Lett 1997;416:259-64.
36. Surinya KH, Forbes BE, Occhiodoro F, Booker GW, Francis GL, Siddle K, et al. An investigation of the ligand binding properties and negative cooperativity of soluble insulin-like growth factor receptors. J Biol Chem 2008;283:5355-63.
37. Brodt P, Fallavollita L, Khatib AM, Samani AA, Zhang D. Cooperative regulation of the invasive andmetastatic phenotypes by different domains of the type I insulin-like growth factor receptor beta subunit. J Biol Chem 2001;276:33608-15.
38. Burnier JV, Wang N, Michel RP, Hassanain M, Li S, Lu Y, et al. Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis. Oncogene 2011;30:3766-83.
39. Rahim S, Uren A. A real-time electrical impedance based technique to measure invasion of endothelial cell monolayer by cancer cells. J Vis Exp 2011;pii:2792.
40. Auguste A, Fallavollita L, Wang N, Bikfalvi A, Brodt P. The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. Am J Pathol 2007;170:1781-92.
41. Long L, Rubin R, Baserga R, Brodt P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 1995;55:1006-9.
42. Long L, Rubin R, Brodt P. Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type 1 insulin-like growth factor receptor. Exp Cell Res 1998;238:116-21.
43. Jansson M, Hallen D, Koho H, Andersson G, Berghard L, Heidrich J, et al. Characterization of ligand binding of a soluble human insulin-like growth factor I receptor variant suggests a ligand-induced conformational change. J Biol Chem 1997;272:8189-97.
44. Davison Z, de Blacquiere GE, Westley BR, May FE. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia 2011;13:504-15.
45. Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 2003;22:974-82.
46. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
47. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999;288:371-8.
48. Rudge JS, Holash J, HyltonD, Russell M, Jiang S, Leidich R, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 2007;104:18363-70.
49. Mourskaia AA, Dong Z, Ng S, Banville M, Zwaagstra JC, O'Connor-McCourt MD, et al. Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone. Oncogene 2009;28:1005-15.
50. Auguste P, Fallavollita L, Wang N, Burnier J, Bikfalvi A, Brodt P. The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. Am J Pathol 2007;170:1781-92.
51. Rechler MM. Insulin-like growth factor binding proteins. Vitam Horm 1993;47:1-114.
52. Korhonen R, Moilanen E. Abatacept, a novel CD80/86-CD28 T cell costimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol 2009;104:276-84.
53. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
54. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991;174:1483-9.
55. Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 2009;9:263-71.
56. Harding TC, Long L, Palencia S, Zhang H, Sadra A, Hestir K, et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci Transl Med 2013; 5:178ra39.
57. Huang C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol 2009;20:692-9.
58. LeRoith D, Roberts CT, Jr. Insulin-like growth factors and their receptors in normal physiology and pathological states. J Pediatr Endocrinol 1993; 6:251-5.
59. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev 2001;22:53-74.
60. Gao J, Chang YS, Jallal B, Viner J. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res 2012;72:3-12.
61. Van den Eynden GG, Majeed AW, Illemann M, Vermeulen PB, Bird NC, Hoyer-Hansen G, et al. The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res 2013; 73:2031-43.